Protocols

GW Pharma cannabinoid to be tested for Alzheimer’s agitation; Acorda revenue plummets as generics eviscerate its franchise

→ Alzheimer’s Research UK is funding a study at King’s College using GW Pharma’s recently approved cannabinoid drug Sativex in dementia. The study will focus on Alzheimer’s patients exhibiting signs of aggression and agitation.

Now that Eli Lilly has acquired Loxo in an $8 billion buyout, Loxo partner Bayer is going its own way on a pair of programs. The pharma company reported Friday morning that it obtained full rights for Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) under their change-of-control clause. Bayer now has exclusive marketing rights in the US.

→ Acorda $ACOR is feeling the effects of the delays it ran into advancing Inbrija to an approval in December. The biotech reported that its Q4 revenue from Ampyra plunged from $167 million for Q4 2017 to $64 million for the most recent period as generics eviscerated its franchise med. Company execs told investors that they aren’t giving projections on what’s to come this year as the biotech’s sales force pushes its new drug in an attempt to establish a new franchise as its cash reserves dwindle.

→ Anchiano Therapeutics has closed its IPO after raising $30.5 million.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->